Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, IL-1RA-blocking Ab (anakinra) and IL-1β-blocking Ab (canakinumab) are already FDA approved as anti-inflammatory biologics for the treatment of rheumatoid arthritis (130) and NLRP3-inflammasome-mediated cryopyrin-associated periodic syndrome (CAPS) (131), respectively.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [131]
Citations
Cites
Natural History and Outcome in Systemic AA Amyloidosis
Lachmann, H. J., Goodman, H. J. B., Gilbertson, J. A., Gallimore, J. R., Sabin, C. A., Gillmore, J. D., & Hawkins, P. N. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070265 · Cited by 1,032
Self-citationSpectrum of clinical features in Muckle‐Wells syndrome and response to anakinra
Hawkins, P. N., Lachmann, H. J., Aganna, E., & McDermott, M. F. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20033 · Cited by 744
Self-citationHoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577 · cited 2×
“Viral infection 0 2 (13) 0 0 Headache 0 2 (13) 0 3 ( 10 )”
URTICARIA, DEAFNESS, AND AMYLOIDOSIS: A NEW HEREDO-FAMILIAL SYNDROME
(1962) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a066967 · Cited by 372
In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes
Lachmann, H. J., Lowe, P., Felix, S. D., Rordorf, C., Leslie, K., Madhoo, S., Wittkowski, H., Bek, S., Hartmann, N., Bosset, S., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082481 · Cited by 312
Self-citationPrimer: inflammasomes and interleukin 1β in inflammatory disorders
Church, L. D., Cook, G. P., & McDermott, M. F. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0681 · Cited by 309
Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Burmester, G. R., Bijlsma, J. W. J., Dougados, M., Emery, P., Keystone, E. C., Klareskog, L., et al. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044941 · Cited by 225
Leslie, K. S., Lachmann, H. J., Bruning, E., McGrath, J. A., Bybee, A., Gallimore, J. R., Roberts, P. F., Woo, P., Grattan, C. E., & Hawkins, P. N. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.12.1591 · Cited by 186 · cited 13×
“Rhinitis 4 (11) 1 (7) 2 (12) 0 Bronchitis 3 (9) 1 ( 7 ) 1 (6) 0”
InfluentialSelf-citationAlten, R., Gram, H., Joosten, L. A., Berg, W. B. V. D., Sieper, J., Wassenberg, S., Burmester, G., van Riel, P., Diaz-Lorente, M., Bruin, G. J., et al. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2438 · Cited by 170
The many worlds of reducing interleukin‐1
Dinarello, C. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21107 · Cited by 104
Research works printed but not linked: 5
- Muckle TJ, 1962, Q J Med, 31, 235
- Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
- Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
- Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
- Maier J, 2008, J Rheumatol, 35, 939
Cited by
Items 301–400 of 869
Parry, T. L., Melehani, J. H., Ranek, M. J., & Willis, M. S. (2015) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2015.00025 · Cited by 46
“Disruption of IL-1 signaling, with either the IL-1-receptor antagonist, Anakinra, or an anti-IL-1β monoclonal antibody, Canakinumab, provides rapid and dramatic resolution of symptoms (70, 71).”
BackgroundThe Eurofever Project: towards better care for autoinflammatory diseases
on behalf of the Eurofever Project, Özen, S., Frenkel, J., Ruperto, N., & Gattorno, M. (2011) · European Journal of Pediatrics · doi:10.1007/s00431-011-1411-z · Cited by 50
“Over 95% of patients achieved complete remission within 4 weeks of treatment [34].”
BackgroundAn Update on the Use of Immunomodulators in Primary Immunodeficiencies
Vignesh, P., Rawat, A. K., & Singh, S. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8591-2 · Cited by 47
Pharmacological treatment options for cryopyrin-associated periodic syndromes
Landmann, E., & Walker, U. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1338946 · Cited by 49
“In CAPS, clinical and serological improvement was noted as early as 24 h after drug administration [97,98].”
BackgroundInfluentialMuckle–Wells syndrome: clinical perspectives
Tran, T.-A. (2017) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s114447 · Cited by 48
Clinical and biochemical landmarks in systemic autoinflammatory diseases
Cantarini, L., Rigante, D., Brizi, M. G., Lucherini, O. M., Sebastiani, G. D., Vitale, A., Gianneramo, V., & Galeazzi, M. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.598546 · Cited by 44
Inflammasome-Mediated Autoinflammatory Disorders
Wilson, S. P., & Cassel, S. L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2209 · Cited by 50
“Use of canakinumab in CAPS resulted in prompt and persistent improvement in clinical and laboratory parameters of inflammation.(25)”
MethodInterleukin 1 receptor (IL-1R1) activation exacerbates toxin-induced acute kidney injury
Privratsky, J. R., Zhang, J., Lu, X., Rudemiller, N. P., Wei, Q., Yu, Y.-R. A., Gunn, M. D., & Crowley, S. D. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00104.2018 · Cited by 47
Rees, D. C., Kılınç, Y., Ünal, S., Dampier, C., Pace, B. S., Kaya, B., Trompeter, S., Odame, I., Mahlangu, J. N., Ünal, Ş., et al. (2022) · Blood · doi:10.1182/blood.2021013674 · Cited by 51
Polyclonal and Monoclonal Antibodies in Clinic
Wootla, B., Đenić, A., & Rodriguez, M. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_5 · Cited by 48
Imhof, L., Meier-Schiesser, B., Frei, P., Kamarachev, J., Rogler, G., Kolios, A. G. A., Navarini, A. A., Contassot, E., & French, L. E. (2015) · Dermatology · doi:10.1159/000371879 · Cited by 44
Review: Beyond the NLRP3 Inflammasome: Autoinflammatory Diseases Reach Adolescence
Gattorno, M., & Martini, A. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37882 · Cited by 45
Russo, R. A. G., Gomes, S. M., Lachmann, H. J., Wynne, K., Rajput, K. M., Eleftheriou, D., Edelsten, C., Hawkins, P. N., & Brogan, P. A. (2013) · Rheumatology · doi:10.1093/rheumatology/ket415 · Cited by 45
Self-citationLipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 47
Chioato, A., Noseda, E., Felix, S., Stevens, M., Giudice, G. D., Fitoussi, S., & Kleinschmidt, A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00175-10 · Cited by 43
“Therefore, it is of high importance to evaluate whether canakinumab might interfere with vaccinations, as inflammatory diseases like gout, sJIA, CAPS, etc., require life-long treatment which may start early in childhood.”
BackgroundInfluentialCryopyrin-Associated Periodic Syndromes: Diagnosis and Management
Miyamae, T. (2012) · Pediatric Drugs · doi:10.2165/11595040-000000000-00000 · Cited by 47
“It has no cross-reactivity with other members of the IL-1 family, including IL-1a.([37]) The mean half-life of canakinumab is 26 days, which is the longest of the three IL-1targeted drugs.”
BackgroundCurrent treatment recommendations and considerations for cryopyrin-associated periodic syndrome
Koné‐Paut, I., & Galeotti, C. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1077702 · Cited by 41
“In patients 2–4 years old, the starting dose is 4 mg/kg, with an escalation to a maximum of 8 mg/kg [25].”
BackgroundInfluentialIlowite, N. T., & Laxer, R. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6581-4.10006-8 · Cited by 42
Kuemmerle-Deschner, J. B., Gautam, R., George, A. T., Raza, S. A., Lomax, K. G., & Hur, P. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001227 · Cited by 43
Self-citationProgress in the pharmacotherapy of gout
Sundy, J. S. (2010) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283369014 · Cited by 43
Canakinumab in Schnitzler Syndrome
Vanderschueren, S., & Knockaert, D. C. (2012) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2012.06.003 · Cited by 40
Edlund, H., Melin, J., Parra-Guillen, Z. P., & Kloft, C. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0208-4 · Cited by 43
“Similarly, nine studies reported a BW-normalised CL, which is also a linear scaling model [23, 50, 59, 79, 86, 92, 94, 117, 121].”
BackgroundLipsker, D. M., Perrigouard, C., Foubert, A., & Cribier, B. J. (2010) · Dermatology · doi:10.1159/000280436 · Cited by 39
Gram, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.023 · Cited by 42
Rieber, N. P., Gavrilov, A., Hofer, L., Singh, A., Öz, H. H., Endres, T., Schäfer, I., Handgretinger, R., Hartl, D., & Kuemmerle-Deschner, J. B. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.01.003 · Cited by 39
Self-citationYokoyama, K., Ikeya, M., Umeda, K., Oda, H., Nodomi, S., Nasu, A., Matsumoto, Y., Izawa, K., Horigome, K., Kusaka, T., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38912 · Cited by 38
Toldo, S. A., Quader, M. A., Salloum, F. N., Mezzaroma, E., & Abbate, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060958 · Cited by 40
“IL-1β blockers are considered the standard of care for the clinical treatment of inflammasomemediated diseases [138–140].”
BackgroundType I IFN-mediated regulation of IL-1 production in inflammatory disorders
Ludigs, K., Parfenov, V., Pasquier, R. D., & Guarda, G. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0989-2 · Cited by 40
Autoinflammation: translating mechanism to therapy
Doherty, T. A., Brydges, S. D., & Hoffman, H. M. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110616 · Cited by 39
Unintended Immunological Consequences of Biologic Therapy
Henrickson, S. E., Ruffner, M. A., & Kwan, M. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0624-7 · Cited by 39
Spectrum of the neurologic manifestations in childhood-onset cryopyrin-associated periodic syndrome
Kilic, H., Şahin, S., Duman, Ç., Adroviç, A., Barut, K., Turanlı, E. T., Yıldırım, S. R., Kızılkılıç, O., Kasapçopur, Ö., & Saltık, S. (2019) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2019.03.006 · Cited by 36
Monogenic autoinflammatory diseases
Russo, R. A. G., & Brogan, P. A. (2014) · Rheumatology · doi:10.1093/rheumatology/keu170 · Cited by 44
Nano-Antagonist Alleviates Inflammation and Allows for MRI of Atherosclerosis
Mog, B. J., Asase, C., Chaplin, A. M. L., Gao, H., Rajagopalan, S., & Maiseyeu, A. (2019) · Nanotheranostics · doi:10.7150/ntno.37391 · Cited by 39
“For example, besides fatal sepsis cases observed in CANTOS trial[5], IL-1β inhibition in systemic juvenile idiopathic arthritis increased risk of urinary tract infections, nasopharyngitis, thrombocytopenia and severe neutropenia[6,7].”
BackgroundThe Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
Carballido, J. M., Regairaz, C., Rauld, C., Raad, L., Picard, D., & Kammuller, M. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00472 · Cited by 40
“Surprisingly, inhibition of IL1 has provided limited efficacy in rheumatic diseases, but it has shown great effects in autoinflammatory conditions mediated by inflammasome activation (7, 15, 16).”
BackgroundInflammasome Activation in Pollution-Induced Skin Conditions
Ferrara, F., Prieux, R., Woodby, B., & Valacchi, G. (2021) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000007617 · Cited by 35
The NLRP1 inflammasome in skin diseases
Burian, M., Schmidt, M. F., & Yazdi, A. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111611 · Cited by 37
Osawa, R., Williams, K. L., & Singh, N. (2010) · Journal of Infection · doi:10.1016/j.jinf.2010.10.002 · Cited by 35
Interleukin‐1 antagonism in acute gout: Is targeting a single cytokine the answer?
Neogi, T. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27635 · Cited by 40
Hashkes, P. J., & Toker, O. (2012) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2012.03.005 · Cited by 35
Maiorino, M. I., Bellastella, G., Giugliano, D., & Esposito, K. (2016) · Endocrine · doi:10.1007/s12020-016-0993-7 · Cited by 34
Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
Mamoudjy, N., Maurey, H., Marie, I., Koné‐Paut, I., & Deiva, K. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0589-1 · Cited by 33
“Canakinumab treatment confirms its efficacy in neurological symptoms in 76% of treated patients [4].”
BackgroundMethodNoè, A., Howard, C. P., Thuren, T. Y., Taylor, A. E., & Skerjanec, A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.004 · Cited by 34
Role of Interleukin‐1 Inhibitors in the Management of Gout
Tran, T. H., Pham, J. T., Shafeeq, H., Manigault, K. R., & Arya, V. A. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1265 · Cited by 34
The Emerging Role of Interleukin-1β in Autoinflammatory Diseases
Lane, T., & Lachmann, H. J. (2011) · Current Allergy and Asthma Reports · doi:10.1007/s11882-011-0207-6 · Cited by 38
“[34, 35] have reported complete clinical remission within 8 days that lasted a median of 100 to 185 days.”
BackgroundSelf-citationNaselli, A., Penco, F., Cantarini, L., Insalaco, A., Alessio, M., Tommasini, A., Maggio, C., Obici, L. P., Gallizzi, R., Cimmino, M. A., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.150962 · Cited by 33
Cardani (2013) · Gastroenterology Research · doi:10.4021/gr556w · Cited by 34
“On the other hand, anti-IL-1 antibodies have proven to be safe for clinical use [28, 29] and effective against DSS-induced acute colitis [30].”
BackgroundEmerging medical therapies for severe alcoholic hepatitis
Tornai, D., & Szabó, G. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0145 · Cited by 36
Vigilance on New-Onset Atherosclerosis Following SARS-CoV-2 Infection
Liu, Y., & Zhang, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.629413 · Cited by 32
“Canakinumab, a fully humanized monoclonal antibody that targets IL-1β, has received approval in many countries as an orphan drug to treat rare heritable chronic inflammatory diseases (87).”
BackgroundAnti-Interleukin-1 Agents in Adult Onset Still's Disease
Giampietro, C., & Fautrel, B. (2012) · International Journal of Inflammation · doi:10.1155/2012/317820 · Cited by 40
“In this paper, we discuss the biology and the role of IL-1 in AOSD pathogenesis and we review the current literature about the utilization of anti-IL-1 agents in clinical practice.”
BackgroundHashkes, P. J., & Toker, O. (2010) · Biologics · doi:10.2147/btt.s7580 · Cited by 33
Periodic Fever Syndromes and Other Inherited Autoinflammatory Diseases
Barron, K. S., & Kastner, D. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24145-8.00047-8 · Cited by 36
Redox distress and genetic defects conspire in systemic autoinflammatory diseases
Varga, G., Gattorno, M., Foell, D., & Rubartelli, A. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.105 · Cited by 31
Biologic response modifiers: Indications, implications, and insights
Davis, B. P., & Ballas, Z. K. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.02.013 · Cited by 33
Treatment strategies for juvenile idiopathic arthritis
Klein, A., & Horneff, G. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386300 · Cited by 31
Targeting inflammasomes in rheumatic diseases
So, A. K.-L., Ives, A., Joosten, L. A. B., & Busso, N. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.61 · Cited by 32
Ait‐Oudhia, S., Lowe, P. J., & Mager, D. E. (2012) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.6 · Cited by 31
“whereas an exponential residual variability error model was used for CRP plasma concentrations: (15)”
MethodKosloski, M. P., Goss, S. L., Wang, S. X., Liu, J., Loebbert, R. W., Medema, J. K., Liu, W. Y., & Dutta, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.764 · Cited by 32
“The Journal of Clinical Pharmacology 2016, 56(12) 1582–1590”
BackgroundThe classification, genetic diagnosis and modelling of monogenic autoinflammatory disorders
Moghaddas, F., & Masters, S. L. (2018) · Clinical Science · doi:10.1042/cs20171498 · Cited by 31
Role of interleukin-1 and inflammasomes in oral disease
Murakami, T., Takahata, Y., Hata, K., & Nishimura, R. (2020) · Journal of Oral Biosciences · doi:10.1016/j.job.2020.07.003 · Cited by 33
Sánchez‐Borges, M., Ansotegui, I. J., Baiardini, I., Bernstein, J., Canonica, G. W., Ebisawa, M., Gómez, R. M., Díaz, S. N. G., Martin, B. L., Morais-Almeida, M., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100546 · Cited by 32
“Differential diagnosis of acute urticaria in pediatric patients patients with cryopirin-associated periodic syndrome,(45) and in urticarial vasculitis.(46)”
BackgroundChang, C. C., & Bachove, I. (2014) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s46017 · Cited by 32
Juvenile idiopathic arthritis: management and therapeutic options
Ruth, N. M., & Passo, M. H. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11413630 · Cited by 33
“Canakinumab is a fully human anti-ILb monoclonal antibody that selectively blocks IL-1b and is administered by subcutaneous injection or intravenous infusion at a dose of 2 mg/kg every 8 weeks [Lachmann et al. 2009].”
MethodGram, H. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.12.003 · Cited by 31
Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes
Li, H., Liu, T., Shi, X., Du, H., Cai, C., Yang, D., Qu, L., Dou, H., Jiao, B., & Jiao, B. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118164 · Cited by 32
Balow, J. E., Ryan, J., Chae, J. J., Booty, M. G., Bulua, A. C., Stone, D. L., Sun, H., Greene, J., Barham, B. K., Goldbach‐Mansky, R. T., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202082 · Cited by 31
Greenan, E., Gallagher, S., Khalil, R., Murphy, C. C., & Gabhann, J. N. (2021) · Viruses · doi:10.3390/v13091856 · Cited by 29
Vergis, N., Patel, V., Bogdanowicz, K., Czyzewska-Khan, J., Keshinro, R., Fiorentino, F., Day, E., Middleton, P., Atkinson, S., Tranah, T. H., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.025 · Cited by 28
“19 Furthermore, in the CANTOS study Q22 those participants with the lowest C-reactive protein after CAN therapy gained the most clinical bene fi t. 20 This suggests either that the dose of CAN was insuf fi cient for participants with AH or that redundancy in Q23 cytokine pathway – maintained in fl…”
Autoinflammatory conditions: when to suspect? How to treat?
Grateau, G., & Duruöz, M. T. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2009.12.009 · Cited by 32
Kambe, N., Nakamura, Y., Saito, M. K., & Nishikomori, R. (2010) · Allergology International · doi:10.2332/allergolint.09-rai-0160 · Cited by 28
Autoinflammation: From monogenic syndromes to common skin diseases
Nguyen, T. V., Cowen, E. W., & Leslie, K. S. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.11.002 · Cited by 28
Self-citationCanakinumab for Childhood Sight-threatening Refractory Uveitis: A Case Series
Brambilla, A., Caputo, R., Cimaz, R., & Simonini, G. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160064 · Cited by 27
Autoinflammatory syndromes: diagnosis and management
Sanctis, S. D., Nozzi, M., Torto, M. D., Scardapane, A., Gaspari, S., de Michele, G., Breda, L., & Chiarelli, F. (2010) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/1824-7288-36-57 · Cited by 31
“Thanks to the advanced techniques in genetics, to date many genes have been recognized in the pathogenesis of periodic syndromes like familial Mediterranean fever (FMF), hyper IgD syndrome (HIDS), tumor necrosis factor receptor associated autoinflammatory syndrome (TRAPS), cryopyrin associated periodic syndromes (CAPS…”
BackgroundInfluentialWalker, U. A., Tilson, H. H., Hawkins, P. N., van der Poll, T., Noviello, S., Lévy, J., Vritzali, E., Hoffman, H. M., & Kuemmerle-Deschner, J. B. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001663 · Cited by 26
Self-citationCremer, P. C., Sheng, C. C., Sahoo, D. H., Dugar, S. P., Prada, R. A., Wang, T. K. M., Hassan, O. K. A., Hernandez-Montfort, J., Wolinsky, D. A., Culver, D. A., et al. (2021) · European Heart Journal Open · doi:10.1093/ehjopen/oeab002 · Cited by 27
“By chance, numerically more patients who received canakinu-mab 600mg had diabetes mellitus [10 (66.7”
BackgroundInfluentialTargeting cytokines and immune checkpoints in atherosclerosis with monoclonal antibodies
Lutgens, E., Joffre, J., van Os, B. W., & Ait‐Oufella, H. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.09.024 · Cited by 28
Current perspectives on therapeutic antibodies
Yoon, S., Kim, Y., Shim, H., & Chung, J. (2010) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-009-3113-1 · Cited by 30
The Expanding Role of Therapeutic Antibodies
Salemi, S., Marković, M., Martini, G., & D’Amelio, R. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2013.863304 · Cited by 27
Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?
Nguyen, P. M., & Putoczki, T. L. (2018) · Cytokine · doi:10.1016/j.cyto.2018.01.008 · Cited by 28
Grosskreutz, C. L., Hockey, H., Serra, D. B., & Dryja, T. P. (2015) · Cornea · doi:10.1097/ico.0000000000000627 · Cited by 26
Protective and detrimental roles of inflammasomes in disease
Saavedra, P. H. V., Demon, D., Gorp, H. V., & Lamkanfi, M. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0485-5 · Cited by 30
Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice
Frising, U. C., Ribó, S., Doglio, M. G., MALISSEN, B., Loo, G., & Wullaert, A. (2022) · EMBO Reports · doi:10.15252/embr.202154339 · Cited by 29
“…Anakinra blocks the binding of both IL-1 a and IL-1 b to the IL-1R, the fact that CAPS patients can be treated with anti-IL-1 b monoclonal antibodies (Lachmann et al , 2009) suggests that the weight gain improvement provided by Anakinra in our model is mediated by blocking IL-1 b activities.”
Canakinumab for the treatment of autoinflammatory very early onset- inflammatory bowel disease
Shaul, E., Conrad, M. A., Dawany, N. B., Patel, T., Canavan, M. C., Baccarella, A., Weinbrom, S., Aleynick, D., Sullivan, K. E., & Kelsen, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972114 · Cited by 25
“Clinically, this can manifest with symptoms of fevers, arthritis, oral ulcers, leukocytosis and elevated inflammatory markers (24) .”
BackgroundHönicke, A.-S., Ender, S. A., & Radons, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1498 · Cited by 27
Nishikomori, R., Izawa, K., Kambe, N., Ohara, O., & Yasumi, T. (2019) · International Immunology · doi:10.1093/intimm/dxz047 · Cited by 29
Therapeutic advances in alcohol-associated hepatitis
Szabó, G., Thursz, M. R., & Shah, V. H. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.025 · Cited by 24
Impact of IL-1 inhibition on fatigue associated with autoinflammatory syndromes
Yadlapati, S., & Efthimiou, P. (2015) · Modern Rheumatology · doi:10.3109/14397595.2015.1069459 · Cited by 24
Bone involvement in monogenic autoinflammatory syndromes
Bader‐Meunier, B., Nieuwenhove, E. V., Breton, S., & Wouters, C. H. (2017) · Rheumatology · doi:10.1093/rheumatology/kex306 · Cited by 24
Cabrera, N., Lega, J., Kassaï, B., Wouters, C. H., Kondi, A., Cannizzaro, E., Woerner, A., Chausset, A., Roethlisberger, S., Jeanneret, C., et al. (2018) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.003 · Cited by 25
Iida, Y., Wakiguchi, H., Okazaki, F., Nakamura, T., Yasudo, H., Kubo, M., Sugahara, K., Yamashita, H., Suehiro, Y., Okayama, N., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4331-8 · Cited by 24
30 Years of Biotherapeutics Development—What Have We Learned?
Ghilardi, N., Pappu, R., Arron, J. R., & Chan, A. C. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101619-031510 · Cited by 27
Adult Onset Still's Disease and Autoinflammation
Efthimiou, P., Moorthy, L. N., Mavragani, C. P., Skokos, D., & Fautrel, B. (2012) · International Journal of Inflammation · doi:10.1155/2012/964751 · Cited by 24
Bioanalysis of Target Biomarker And Pk/Pd Relevancy During The Development of Biotherapeutics
Lee, J. W., & Salimi-Moosavi, H. (2012) · Bioanalysis · doi:10.4155/bio.12.220 · Cited by 24
Successful Treatment of Refractory Adult-Onset Still Disease With Canakinumab
Barsotti, S., Neri, R., Iacopetti, V., d’Ascanio, A., Talarico, R., Tripoli, A., & Bombardieri, S. (2014) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000082 · Cited by 24
Nakanishi, H., Yamada, S., Kita, J., Shinmura, D., Hosokawa, K., Sahara, S., & Misawa, K. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.865763 · Cited by 25
“Weekly dosing of rilonacept or every 2 months of canakinumab provided a similar efficacy in patients with MWS and FCAS in clinical trials (30, 31).”
BackgroundAutoinflammatory syndromes as causes of fever of unknown origin
Lachmann, H. J. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-3-295 · Cited by 25
Self-citationHoux, L., HACHULLA, E., Koné‐Paut, I., Quartier, P., Touitou, I., Guennoc, X., Grateau, G., Hamidou, M. A., Neven, B., Berthelot, J., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39292 · Cited by 23
“that inhibit the effects of IL-1, such as anakinra (9,20,21), canakinumab (22,23), and rilonacept (8,10), Table 1.”
BackgroundSelf-citationMonogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient
Özen, S., & Demir, S. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0232-6 · Cited by 23
Quartier, P., Rodrigues, F., & Georgin‐Lavialle, S. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.09.002 · Cited by 25
Self-citationReula, A. J. T. I., Cochino, A., Martins, A., Angosto-Bazarra, D., de Landazuri, I. O., Mensa‐Vilaró, A., Cabral, M., Baroja‐Mazo, A., Baños, M. C., Lobato, Z., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01298-2 · Cited by 23
Álvarez-Simón, D., Yahia, S. A., de Nadaï, P., Audousset, C., Chamaillard, M., Boneca, I. G., & Tsicopoulos, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.928886 · Cited by 22
Metadata
- Authors
- Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
- Affiliations
- University College London (GB)
- Universitätsklinikum Tübingen (DE)
- University of California, San Francisco (US)
- Université de Lille (FR)
- Hôpital Necker-Enfants Malades (FR)
- Novartis (Switzerland) (CH)
- Novartis (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-06-04
- Volume
- 360
- Issue
- 23
- Pages
- 2416-2425
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149374693
- Cited by
- 869
- References
- 19
- Citations by year
- 2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
- FWCI
- 35.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.